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Paragangliomas are rare neuroendocrine tumors arising from the ganglia of the sympa-
thetic or parasympathetic nervous system. Less than 160 cases of intrapericardial or
intracardiac paragangliomas have been reported in the English language peer-reviewed
medical literature. Here, we report a case of intrapericardial paraganglioma, which illus-
trates some typical multimodality imaging features of this rare entity.
© 2016 the Authors. Published by Elsevier Inc. under copyright license from the University
of Washington. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Case report
We report a case of a 25-year-old woman who was initially
assessed with echocardiography for investigation of palpita-
tions and mild exertional dyspnea. Transthoracic echocar-
diogram demonstrated a 6-cm mediastinal mass of
heterogeneous echotexture in the right atrioventricular
groove, compressing and deforming the right ventricle and
right atrium (RA; Fig. 1).
The patient then underwent a noneEKG-gated computer
tomography scan of the chest with intravenous contrast. It
revealed a well-defined mass in the right atrioventricular
groove, indenting theRAandrightventricularoutflowtract, and
abutting the aortic root and distal superior vena cava (Fig. 2).
Themass was hyperenhancingwith a thin hypoenhancing rim
and a central area of stellate hypoenhancement, reminiscent of
a central scar of hepatic fibronodular hyperplasia. The lesion
contained neither detectable fat nor calcifications. It appeared
intrapericardial and possibly intra-atrial.lared that no competing
il.mcgill.ca (A. Semionov
Elsevier Inc. under copy
se (http://creativecommoThe subsequent cardiacmagnetic resonance imaging again
demonstrated a well-defined right intrapericardial mass,
showing avid enhancement with intravenous gadolinium
contrast, and central stellate “scar” (Fig. 3). The appearance of
the mass on cine images, and its broad base along the wall of
the right cardiac chambers favored a mass centered on the
epicardium.
(18)F-fluorodeoxyglucose positron emission tomography
was also performed and showed a 6-cm intensely hypermet-
abolic lesion in the right heart with standardized uptake value
of up to 31 and central necrosis (Fig. 4).
Coronary angiography was performed next and showed
the mass's blood supply from a prominent branch of the
proximal right coronary artery (Fig. 5). The mass enhanced
rapidly and washed out quickly via a confluence of small
veins, which drained into the coronary sinus.
An indium-111 octreotide single-photon emission
computed tomography at 4 and 24 hours postadministration
of the radiopharmaceutical was performed next. The lesioninterests exist.
).
right license from the University of Washington. This is an open
ns.org/licenses/by-nc-nd/4.0/).
Fig. 1 e Transthoracic cardiac ultrasound demonstrating a
heterogeneous mass (arrow) along the wall of the right
heart chambers, at the level of the atrioventricular groove,
abutting the aortic root, indenting and deforming the RA
and RV. LA, left atrium; LV, left ventricle; RV, right
ventricle; AoR, aortic root.
Fig. 2 e Contrast-enhanced computed tomography of the
chest demonstrating a well-defined hyperenhancing mass
(arrows) with a thin hypoenhancing rim, and a central area
of stellate hypoenhancement, in the right atrioventricular
groove, indenting the RA and right ventricle outflow tract.
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suspected diagnosis of a cardiac paraganglioma.
An iodine-131 metaiodobenzylguanidine (I-131 MIBG)
scintigraphy was also performed and showed mild heteroge-
neous radiotracer accumulation in the RA at the site of the
mass (Fig. 7).
The patient eventually underwent surgical resection of the
mass, with final pathology confirming the diagnosis of intra-
pericardial paraganglioma (IPP).Discussion
Paragangliomas are rare neuroendocrine tumors closely
related to pheochromocytomas, tumors of chromaffin-
positive cells of the adrenal glands [1]. Extra-adrenal para-
gangliomas may arise anywhere in the body, with the ma-
jority found in the abdomen [2]. Approximately 2% of
paragangliomas occur in the thorax. IPPs are very rare. In 2014
Wang et al. [3] published a review article, where they identi-
fied 158 reported cases of cardiac paragangliomas in the En-
glish language PubMed database. They found male-to-female
ratio of 0.86 and mean age at diagnosis of 39.7 years.
A minority of patients with IPP (about 8%) may be
completely asymptomatic, and lesions might be found inci-
dentally on imaging [4]. When present, symptoms in patients
with IPP are usually secondary to excessive catecholamine
excretion by the tumor, resulting in headaches, palpitations,
diaphoresis, and systemic arterial hypertension [3].
On cross-sectional imaging, IPP usually appear as large, 3-8
cm, well-defined and often encapsulated heterogeneous
masses [5]. Internal calcifications can be occasionally present
[5]. IPP are hypervascular, demonstrating avid enhancement
and rapid washout on contrast studies, and a hypoenhancing
central area due to necrosis [6]. Most of the IPPs arise from the
epicardium, and the majority are found in the interatrial and
atrioventricular grooves or at the root of the great vessels,
areas where parasympathetic ganglia normally exist [3].
The IPP are supplied by the coronary arteries, the majority
(57.9%) fed by the right coronary artery [3].
At echocardiography, paragangliomas usually appear as
echogenic masses and could be mistaken for myxomas, when
arising from the interatrial septum [6]. Unlike myxomas,
however, paragangliomas have a broad base [6]. Compression
of adjacent vascular structures and encasement of the coro-
nary arteries may be seen [6].
Fig. 4 e Axial image of (18)F-fluorodeoxyglucose positron
emission tomography shows an intensely hypermetabolic
lesion in the right heart (black arrows) with central
photopenia suggestive of necrosis (white arrow).
Fig. 5 e Angiography of the right coronary artery (outlined
arrow) shows rapid heterogeneous contrast opacification
of the mass (simple arrows).
Fig. 3 e (A) Cardiac MRI, axial steady-state free precession
(SSFP) image demonstrates a well-defined heterogeneous
right intrapericardial mass (arrows), which is hyperintense
relative to the myocardium. (B) Cardiac MRI T1 FatSat axial
images pre- (a) and post-intravenous (b) gadolinium
contrast administration, demonstrating avid enhancement
(white arrows) of the mass, and nonenhancing central
stellate “scar” (black arrow). LV, left ventricle; RV, right
ventricle; IVC, inferior vena cava; MRI, magnetic resonance
imaging.
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signal intensity on T2-weighted images, similar to abdom-
inal paragangliomas, and T1 signal isointense to muscle [5].
I-123 or I-131 MIBG scintigraphy is commonly used for
localization of neuroendocrine tumors. The reported sensi-
tivity for IPP detection with MIBG screening is 75% [3]. MIBGscintigraphy must be interpreted with caution, as multiple
drugs, such as calcium channel blockers, tricyclic antide-
pressants, labetalol, and sympathomimetics can interfere
with the uptake of MIBG causing false-negative results [7].
IPP are expected to be positive on positron emission to-
mography with reported sensitivity of 100% [3].
Indium-111 octreotide is currently the agent of choice
for nuclear medicine imaging of paragangliomas [8].
Octreotide binds to somatostatin receptors which most
Fig. 6 e Indium-111 octreotide single-photon emission computed tomography at 4 hours (A) and 24 hours (B)
postadministration of the radiopharmaceutical shows that the right cardiac lesion (arrows) is positive for octreotide uptake.
Fig. 7 e I-131MIBG scintigraphy showsmild heterogeneous
radiotracer accumulation in the right heart (arrow).
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In-111 octreotide scanning for IPP detection showed 100%
sensitivity [3].
The treatment of symptomatic cases of IPP is surgical.
Because the tumors are highly vascular and tend to involve
the coronary arteries, surgical resection is often difficult [4]. In
cases where surgical resection is impossible, cardiac trans-
plantation is considered a potential treatment option [2]. In all
patients, life-long surveillance for recurrence should be
performed.
In conclusion, IPPs are very rare tumors of the heart,
making themunusual suspects during the initial evaluation of
a mediastinal or cardiac mass. Multimodality imaging is
essential for diagnosis, treatment, and surgical planning as
well as post-treatment surveillance.r e f e r e n c e s
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